伴有新的t(11;18)(q23;q21.2)易位和KMT2A-ME2（MLL-ME2）融合基因的治疗相关急性髓系白血病的长期缓解
Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
作者信息
Szotkowski Tomáš, Jarošová Marie, Zimmermannová Olga, Meyer Claus, Marschalek Rolf, Zuna Jan, Hubáček Jaromír, Indrák Karel
机构信息
Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
出版信息
Cancer Genet. 2015 Dec;208(12):610-4. doi: 10.1016/j.cancergen.2015.09.004. Epub 2015 Sep 15.
We describe a unique case of a woman with acute myeloid leukemia with a new, previously undescribed translocation, t(11;18)(q23;q21.2), affecting the KMT2A (MLL) gene and resulting in an KMT2A(MLL)-ME2 fusion. This disease occurred secondarily following chemotherapy for a different acute myeloid leukemia with the recurrent genetic abnormality inv(16)(p13.1;q22). The secondary leukemia was treated with intensive chemotherapy without allogeneic hematopoietic cell transplantation. Complete remission lasting more than 10 years has been achieved with concurrent and sustained remission of the primary leukemia.
我们描述了一名患有急性髓系白血病的女性的独特病例，该病例存在一种新的、此前未描述过的易位，即t(11;18)(q23;q21.2)，它影响KMT2A（MLL）基因并导致KMT2A(MLL)-ME2融合。该疾病继发于另一种患有复发性遗传异常inv(16)(p13.1;q22)的急性髓系白血病的化疗之后。继发性白血病采用强化化疗进行治疗，未进行异基因造血细胞移植。原发性白血病同时持续缓解，已实现持续超过10年的完全缓解。
Zotero 插件